McKesson (MCK) Promotes Mark Walchirk to U.S. Pharma President

McKesson Corp. (NYSE: MCK) announced that Mark Walchirk has been named president, McKesson U.S. Pharmaceutical, effective immediately. Walchirk, who was most recently chief operating officer of McKesson Specialty Health, has held numerous leadership roles at McKesson for the last 11 years, including chief operating officer of McKesson U.S. Pharmaceutical. Walchirk succeeds Brian Tyler, who was recently appointed executive vice president of corporate strategy and business development, McKesson Corporation.

Walchirk joined McKesson in 2001 and spent more than eight years in progressive leadership roles within McKesson’s U.S. Pharmaceutical business before being appointed president of McKesson Specialty Care Solutions in 2009. He led McKesson’s integration of US Oncology and assumed the role of chief operating officer for the newly combined organization, McKesson Specialty Health. In this role, he helped lead the business to record growth and introduce new solutions that empower the community patient care delivery system.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• McKesson (MCK) PT Raised to $1,000 at Barclays
• Skyward Group CFO to retire in 2027, successor named
• Natuzzi signs definitive CEO agreement, identity pending shareholder vote